TY - JOUR
T1 - Fertility and reproductive technology use in testicular cancer survivors in Japan
T2 - A multi-institutional, cross-sectional study
AU - Yamashita, Shinichi
AU - Kakimoto, Kenichi
AU - Uemura, Motohide
AU - Kishida, Takeshi
AU - Kawai, Koji
AU - Nakamura, Terukazu
AU - Goto, Takayuki
AU - Osawa, Takahiro
AU - Yamada, Shigeyuki
AU - Nishimura, Kazuo
AU - Nonomura, Norio
AU - Kojo, Kosuke
AU - Shiraishi, Takumi
AU - Ukimura, Osamu
AU - Ogawa, Osamu
AU - Shinohara, Nobuo
AU - Suzukamo, Yoshimi
AU - Ito, Akihiro
AU - Arai, Yoichi
N1 - Funding Information:
This work was supported in part by Grants‐in‐Aid for Scientific Research from the Japan Society for the Promotion of Science (18K09185). The authors thank Juntaro Koyama, Shinji Fujii, Takuma Sato, Shuichi Shimada, Yoshihide Kawasaki, Naoki Kawamorita and Koji Mitsuzuka (Tohoku University Graduate School of Medicine) for their assistance in data collection.
Funding Information:
This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (18K09185). The authors thank Juntaro Koyama, Shinji Fujii, Takuma Sato, Shuichi Shimada, Yoshihide Kawasaki, Naoki Kawamorita and Koji Mitsuzuka (Tohoku University Graduate School of Medicine) for their assistance in data collection.
Publisher Copyright:
© 2021 The Japanese Urological Association
PY - 2021/10
Y1 - 2021/10
N2 - Objective: To evaluate fertility and use of reproductive technology of testicular cancer survivors in a multi-institutional, cross-sectional study. Methods: This study recruited testicular cancer survivors who were followed after treatment for testicular cancer at eight high-volume institutions between 2018 and 2019. The participants completed the questionnaires on marital status, fertility and use of reproductive technology. Results: A total of 567 testicular cancer survivors, with a median age of 43 years, responded to the questionnaire. Chemotherapy was given to 398 survivors, including three cycles of cisplatin-based chemotherapy in 106 patients and four cycles in 147 patients. Among 153 survivors who attempted sperm cryopreservation, 133 (87%) could preserve sperm. Of the 28 survivors whose cryopreserved sperm was used, 17 (61%) fathered children. Of the 72 survivors who fathered children without the use of cryopreserved sperm, 59 (82%) fathered naturally. Whereas 33 (20%) of 169 survivors treated without chemotherapy fathered children without using cryopreserved sperm, 39 (10%) of 398 treated with chemotherapy fathered children (P < 0.05). Furthermore, the paternity rate was 12% and 5% in testicular cancer survivors with three and four cycles of cisplatin-based chemotherapy, respectively (P < 0.05). However, of 121 survivors who wanted to have children, 14 (12%) received counseling about infertility treatment. Conclusions: Testicular cancer survivors preserving their sperm have a higher paternity rate after chemotherapy, especially after four cycles, than those not using cryopreserved sperm. Physicians who give chemotherapy for testicular cancer need to take particular care not only with respect to recurrence of testicular cancer, but also to post-treatment fertility.
AB - Objective: To evaluate fertility and use of reproductive technology of testicular cancer survivors in a multi-institutional, cross-sectional study. Methods: This study recruited testicular cancer survivors who were followed after treatment for testicular cancer at eight high-volume institutions between 2018 and 2019. The participants completed the questionnaires on marital status, fertility and use of reproductive technology. Results: A total of 567 testicular cancer survivors, with a median age of 43 years, responded to the questionnaire. Chemotherapy was given to 398 survivors, including three cycles of cisplatin-based chemotherapy in 106 patients and four cycles in 147 patients. Among 153 survivors who attempted sperm cryopreservation, 133 (87%) could preserve sperm. Of the 28 survivors whose cryopreserved sperm was used, 17 (61%) fathered children. Of the 72 survivors who fathered children without the use of cryopreserved sperm, 59 (82%) fathered naturally. Whereas 33 (20%) of 169 survivors treated without chemotherapy fathered children without using cryopreserved sperm, 39 (10%) of 398 treated with chemotherapy fathered children (P < 0.05). Furthermore, the paternity rate was 12% and 5% in testicular cancer survivors with three and four cycles of cisplatin-based chemotherapy, respectively (P < 0.05). However, of 121 survivors who wanted to have children, 14 (12%) received counseling about infertility treatment. Conclusions: Testicular cancer survivors preserving their sperm have a higher paternity rate after chemotherapy, especially after four cycles, than those not using cryopreserved sperm. Physicians who give chemotherapy for testicular cancer need to take particular care not only with respect to recurrence of testicular cancer, but also to post-treatment fertility.
KW - EORTC QLQ-TC26
KW - cross-sectional study
KW - fertility
KW - survivor
KW - testicular cancer
UR - http://www.scopus.com/inward/record.url?scp=85110929084&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110929084&partnerID=8YFLogxK
U2 - 10.1111/iju.14645
DO - 10.1111/iju.14645
M3 - Editorial
C2 - 34278620
AN - SCOPUS:85110929084
VL - 28
SP - 1047
EP - 1052
JO - International Journal of Urology
JF - International Journal of Urology
SN - 0919-8172
IS - 10
ER -